Why do people search for a BPC-157 dosing chart?
BPC-157 has generated significant interest in recovery-oriented, athletic, and biohacking communities based on an extensive body of preclinical research. Rodent studies have explored its potential effects on connective tissue, gastrointestinal health, and neurological pathways. The natural next question for anyone who has read that literature is: how much, how often, and by what route?
That’s a reasonable scientific question. The honest answer is that no validated human dosing protocol exists. What does exist is a set of doses used in animal studies, widely circulated online dosing extrapolations of uncertain provenance, and a growing body of anecdotal reports — none of which constitute a clinical standard of care.
What does the preclinical literature actually use?
The BPC-157 research literature — primarily authored by Predrag Sikiric and colleagues at the University of Zagreb — spans hundreds of animal studies. Across that body of work, the most commonly used doses fall into these ranges:
- Subcutaneous and intraperitoneal injection studies: Most frequently 10 μg/kg and 100 μg/kg in rodent models. Some studies used as low as 1 μg/kg. The dose response has not been systematically characterized across the full range of studied effects.
- Oral administration studies: Some gastrointestinal and systemic studies used BPC-157 dissolved in drinking water, typically in a range of 10 to 100 μg/kg/day.
- Frequency: Most protocols in the literature used once-daily administration for periods ranging from several days to several weeks. Longer-term data is sparse.
| Route (animal studies) | Dose range observed | Notes |
|---|---|---|
| Subcutaneous injection | 1–100 μg/kg | Most common route in connective-tissue studies; systemic or local site |
| Intraperitoneal injection | 10–100 μg/kg | Standard rodent route; not a human administration method |
| Oral (drinking water) | 10–100 μg/kg/day | GI-focused studies; oral bioavailability in humans unconfirmed |
| Frequency (all routes) | Once daily | Typical protocol; durations ranged from days to several weeks |
All figures are from preclinical rodent studies. No human clinical dosing protocols have been established.
These are rat and mouse doses. To extrapolate to humans, researchers would typically apply an allometric scaling formula that accounts for body surface area differences between species. This calculation produces a rough “human equivalent dose,” but that equivalent has not been validated in clinical trials — it is a pharmacological estimation, not a clinical recommendation.
The widely shared 200–500 mcg/day BPC-157 figure isn’t a clinical protocol — it’s allometric scaling and forum anecdote dressed up as a dosing chart.
Why are online BPC-157 dosing charts unreliable?
Online dosing charts for BPC-157 circulate widely on forums, supplement sites, and biohacking communities. Most cite doses in the range of 200 to 500 micrograms per day, divided or in single doses, administered subcutaneously. A few common routes claim doses as high as 1000 micrograms.
The problem is the provenance of these numbers. None of them come from published human clinical trials — because no large-scale human clinical trials exist. They appear to originate from:
- Allometric scaling from rodent doses (inherently imprecise)
- Community anecdote aggregated on forums
- Sellers of gray-market peptides who have commercial interest in accessible dosing information
- Citation chains that trace back to the same informal sources
There is no consensus. There is no clinical validation. What is presented as a “dosing chart” is more accurately described as collective anecdote. That is not nothing, but it is far removed from the standard of evidence that informs legitimate medical dosing.
What safety consideration do dosing discussions often skip?
Most online BPC-157 dosing discussions focus on how much to take. Fewer address what is unknown about human safety at any dose.
BPC-157 has demonstrated a favorable safety profile in animal studies across a range of doses. That is a genuine positive signal. But the unknowns for humans remain substantial:
- Angiogenesis concerns: BPC-157’s proposed interaction with VEGF pathways raises theoretical questions for individuals with conditions where angiogenesis may be clinically significant. This is speculative but not dismissible.
- Drug interactions: No systematic human drug interaction data exists. Combining BPC-157 with prescription medications, anticoagulants, or other biologics is uncharted territory.
- Long-term effects: Animal studies used short durations. The effects of sustained BPC-157 administration over months or years in humans are unknown.
- Source quality outside regulated channels: BPC-157 is commonly obtained from gray-market research chemical suppliers. These products carry significant risks related to purity, sterility, and accurate peptide concentration. A “200 mcg dose” from an unverified source may contain significantly more, less, or something else entirely.
What does BPC-157’s regulatory status mean?
BPC-157 is not an FDA-approved drug and is not currently on FDA’s 503A Bulks List, which is the list of bulk substances a 503A pharmacy may use in compounding.
That status reflects the FDA’s assessment of the current evidence base, not a final scientific judgment, and it is in active transition. On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee met to review BPC-157 for addition to the list. Any recommendation from that committee is non-binding, and FDA has not issued a final determination.
Separately, the U.S. Department of Health and Human Services announced in February 2026 an intent to reclassify certain peptides, potentially including BPC-157. As of publication, this announcement has not been formally published in the Federal Register and carries no legal effect.
What alternatives are available through legal compounding?
For patients interested in clinician-supervised peptide protocols oriented toward recovery and repair, several Category 1 peptides are legally available through licensed 503A compounding pharmacies:
- Sermorelin — A growth hormone releasing hormone (GHRH) analog studied for growth hormone secretion support, recovery, and body composition. Category 1 status, available by prescription from licensed 503A pharmacies.
- Recovery & Repair program consultation — For patients whose primary interest overlaps with BPC-157’s studied applications (connective tissue, GI health, recovery), a clinical consult can evaluate which legally available therapies may address their goals. See the Recovery & Repair program.
Frequently asked questions
What dose of BPC-157 was used in animal studies?
The preclinical literature on BPC-157 spans a wide range of doses. Rodent studies have most commonly used doses in the range of 10 to 100 micrograms per kilogram of body weight, administered via subcutaneous, intraperitoneal, or oral routes. These are animal doses — extrapolating them to human dosing is scientifically imprecise and not validated by controlled human trials.
Is there a proven human BPC-157 dosing protocol?
No. There are no published, large-scale, randomized controlled trials in humans that have established safe and effective BPC-157 dosing. Dosing ranges circulating in online communities are informal extrapolations from animal studies, not clinically validated protocols. BPC-157 is also not an FDA-approved drug and is not currently on FDA's 503A Bulks List, so no regulator has reviewed a dose.
What is the difference between subcutaneous and oral BPC-157 in research?
Preclinical studies have explored both routes. Subcutaneous injection was used in most connective tissue and injury-focused studies. Oral administration has been studied for gastrointestinal applications. Research suggests BPC-157 may retain some activity orally due to its gastric origin, but this remains a preclinical finding and has not been confirmed in controlled human trials.
Why are BPC-157 dosing charts online unreliable?
Dosing charts for BPC-157 found on supplement sites, bodybuilding forums, and biohacking communities are based on informal extrapolations from rodent data, anecdotal reports, and commercial interest — not validated human clinical data. Without Phase I through Phase III human trials, there is no scientific basis for a definitive human dosing chart.
What peptides are legally available with similar research interests?
Sermorelin is a Category 1 peptide with an established compounding pathway, available through licensed 503A pharmacies with a clinician prescription. It has been studied for growth hormone secretion support, recovery, and body composition in contexts that overlap with some of the interests driving BPC-157 searches.
